Doug Drysdale is the CEO at Cybin, a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Their goal is to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During Doug’s 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.
Before Cybin, Doug was Commercial Products Manager at DuPont Merck, Director of BD at Elan, VP of M&A at Actavis Group, CEO of Norwich Pharmaceuticals and Alvogen, CEO of Pernix Therapeutics, and CEO of Tedor Pharma.
The Challenges of Running a Public Company | Transforming Psychiatric Treatments Through Psychedelic Compounds | Developing Breakthrough Therapies in Depression & Anxiety
Jumping from BD to M&A | Leveraging Debt for Strategic Acquisitions | The Importance of Cultural Fit in Successful Deals | Making an Impact at Norwich, Alvogen, & Pernix Therapeutics
Deals Only Get Done in Person | Learning Financing Through a Company’s Hardship | Bureaucracy in the Workplace | How to Educate Yourself to Determine Good Licensing Deals
Start listening to TBSP episodes on your favorite platform. Subscribe to stay up to date on new episodes.
